Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveil...
Saved in:
Main Authors: | Jing Nie (Author), Huina Wu (Author), Lei Sun (Author), Yanjiao Ding (Author), Yepeng Luan (Author), Jiyong Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021) -
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
by: Yamin Shu, et al.
Published: (2022) -
Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
by: Yin Shi, et al.
Published: (2023) -
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018) -
Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib
by: Kai Zhu, et al.
Published: (2024)